EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis

Chuan-Jian Shi, Feng-Xiang Pang, Yu-He Lei, Li-Qiang Deng, Fu-Zhen Pan, Zhi-Qing Liang, Tian Xie, Xian-Lin Wu, Yu-Yan Wang, Yan-Fang Xian, Wei-Qiang Zeng, Han-Li Lin und 1 weitere

Drug Resistance Updates · 2025-01 · 78 · 101181

DOI: 10.1016/j.drup.2024.101181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-01. Verfasst von Chuan-Jian Shi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518000, PR China; Shenzhen Traditional Chi…. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Ferroptosis. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging evidence demonstrates that long non-coding RNAs (lncRNAs) play a crucial role in sorafenib resistance in hepatocellular carcinoma (HCC), and lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a dysregulated lncRNA in sorafenib-resistant HCC cells. However, the underlying regulatory mechanisms of MALAT1 in sorafenib-resistant HCC cells remain unclear. In the present study, we demonstrated that 5-methylcytosine (m5C) methylation catalyzed by NSUN2 and ALYREF contributed to the RNA stability and upregulation of MALAT1. The NSUN2/ALYREF/MALAT1 signaling axis was activated in sorafenib-resistant cells, and the upregulation of MALAT1 inhibited sorafenib-induced ferroptosis to drive sorafenib resistance. Mechanistically, MALAT1 maintained the mRNA stability of SLC7A11 by directly binding to ELAVL1 and stimulating its cytoplasmic translocation. Furthermore, we explored a new synergetic strategy for the treatment of HCC by combining MALAT1 inhibitor MALAT1-IN1 with sorafenib. The results demonstrated that MALAT1-IN1 significantly enhanced sorafenib efficacy for the treatment of HCC both in vitro and in vivo. Collectively, our work brings new insights into the epigenetic mechanisms of sorafenib resistance and offers an alternative therapeutic strategy targeting ferroptosis for sorafenib-resistant HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularLiver NeoplasmsFerroptosisRNA, Long NoncodingDrug Resistance, Neoplasm5-MethylcytosineELAV-Like Protein 1Amino Acid Transport System y+HumansAnimalsMiceAntineoplastic AgentsGene Expression Regulation, NeoplasticMethylationCell Line, Tumor

Stichwörter der Autor:innen

FerroptosisHepatocellular carcinomaMALAT1SLC7A11Sorafenib resistancem(5)C methylation

Substanzen

SorafenibRNA, Long NoncodingMALAT1 long non-coding RNA, humanSLC7A11 protein, human5-MethylcytosineELAV-Like Protein 1Amino Acid Transport System y+ELAVL1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518000, PR China; Shenzhen Traditional Chinese Medicine Oncology Medical Center, Shenzhen, Guangdong 518000, PR…
  • Department of Traditional Chinese Medicine, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, PR China.
  • Research Institute, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518000, PR China.
  • Department of Pharmacy, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 510086, PR China.
  • School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, PR China.

Zitieren

APA

Shi, C. J., Pang, F. X., Lei, Y. H., Deng, L. Q., Pan, F. Z., Liang, Z. Q., Xie, T., Wu, X. L., Wang, Y. Y., Xian, Y. F., Zeng, W. Q., Lin, H. L., & Zhang, J. F. (2025). 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis. Drug Resistance Updates, 78, 101181. https://doi.org/10.1016/j.drup.2024.101181

Vancouver

Shi CJ, Pang FX, Lei YH, Deng LQ, Pan FZ, Liang ZQ, et al. 5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis. Drug Resistance Updates. 2025;78:101181. doi:10.1016/j.drup.2024.101181

BibTeX
@article{Shi2025,
  author = {Shi, Chuan-Jian and Pang, Feng-Xiang and Lei, Yu-He and Deng, Li-Qiang and Pan, Fu-Zhen and Liang, Zhi-Qing and Xie, Tian and Wu, Xian-Lin and Wang, Yu-Yan and Xian, Yan-Fang and Zeng, Wei-Qiang and Lin, Han-Li and Zhang, Jin-Fang},
  title = {5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1/SLC7A11-mediated ferroptosis},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {78},
  pages = {101181},
  doi = {10.1016/j.drup.2024.101181}
}
Kostenlos starten →